Head to Head Contrast: Sanara MedTech (NASDAQ:SMTI) vs. Bone Biologics (NASDAQ:BBLG)

Sanara MedTech (NASDAQ:SMTI) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Earnings & Valuation

This table compares Sanara MedTech and Bone Biologics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$64.99 million	4.37	-$4.30 million	($0.59)	-54.97
Bone Biologics	N/A	N/A	-$8.95 million	N/A	N/A

Sanara MedTech has higher revenue and earnings than Bone Biologics.

Volatility & Risk

Sanara MedTech has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, Bone Biologics has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500.

Insider and Institutional Ownership

8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 54.1% of Sanara MedTech shares are owned by insiders. Comparatively, 13.0% of Bone Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Sanara MedTech and Bone Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-9.07%	-15.17%	-8.94%
Bone Biologics	N/A	-151.99%	-121.03%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Sanara MedTech and Bone Biologics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	0	0	1	0	3.00
Bone Biologics	0	0	0	0	N/A

Sanara MedTech currently has a consensus price target of $44.00, suggesting a potential upside of 33.94%. Given Sanara MedTech’s higher possible upside, equities research analysts plainly believe Sanara MedTech is more favorable than Bone Biologics.

Summary

Sanara MedTech beats Bone Biologics on 8 of the 10 factors compared between the two stocks.

About Sanara MedTech

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.